David Carbone
Director, James Thoracic Center · Ohio State University Hospital
Credentials: · · · · ·
History
PresentJames Thoracic Center · Ohio State University Hospital
- Present
Translational Therapeutics Program · Ohio State University Hospital
- 1988–1991
Hematology and Medical Oncology
- 1985–1988
Internal Medicine
- 1981–1985
Research
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2017 · First of 30 authors · 2,096 citations
Nature Medicine · 1996 · Last of 8 authors · 1,598 citations
ROS1 rearrangements define a unique molecular class of lung cancers
Journal of Clinical Oncology · 2012 · 1,250 citations
- KH
35 papers
34 papers · 3 as a fellow
31 papers
30 papers
- GO
28 papers
- PM
26 papers · 13 as a fellow
- AG
23 papers
23 papers
Grants
- 1997–2031
National Cancer Institute · P30
Project lead · $612.3K · Ohio State University
- 2019–2027
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
National Cancer Institute · UG1
PI · $5.1M · Emory University
- 2021–2027
Targeting Immunosuppressive Adenosine in Patients with Metastatic Non-Small Cell Lung Cancer
National Cancer Institute · R01
Contact PI · $3M · Ohio State University
- 2019–2026
OSU as a Network Lead Academic Participating Site for the NCI NCTN
National Cancer Institute · UG1
PI · $7.8M · Ohio State University
Clinical trials
- 2008
Study chair · Completed
ECOG-ACRIN Cancer Research Group
- 2007–2013
Study chair · Completed · Phase 2
Vanderbilt-Ingram Cancer Center
- 2006
Study chair · Completed
ECOG-ACRIN Cancer Research Group
- 1998–2007
Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed
Study chair · Completed · Phase 1
Eastern Cooperative Oncology Group